PROOF-OF-CONCEPT STUDY FOR NEW INTRAOCULAR LENS, MODEL C0002

NCT ID: NCT05531292

Last Updated: 2025-07-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 106 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-11-22
• Study Completion Date: 2025-05-20

Brief Summary

Prospective, two-arm, randomized, bilateral, subject/evaluator-masked clinical study to evaluate the distance visual acuity, peripheral refractive error and functional vision of the EPV IOL compared to a standard monofocal control IOL.

Conditions

Cataracts

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Study Lens

investigational IOL Model C0002

Group Type: EXPERIMENTAL

Model C0002

Intervention Type: DEVICE

Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.

Control Lens

control IOL Model ZCB00/DCB00

Group Type: ACTIVE_COMPARATOR

Model ZCB00/DCB00

Intervention Type: DEVICE

Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.

Interventions

Model C0002

Eligible subjects will be randomized in a 1:1 ratio to the investigational IOL Model C0002 in both eyes for the duration of the study.

Intervention Type: DEVICE

Model ZCB00/DCB00

Eligible subjects will be randomized in a 1:1 ratio to the control IOL Model ZCB00 in both eyes for the duration of the study.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age of study population between 60-75 years;

2. Bilateral cataracts for which cataract extraction and posterior chamber IOL implantation have been planned for both eyes;

3. Cataractous lens changes, as demonstrated by best-corrected distance visual acuity (BCDVA) of 0.50 decimal or worse (6/12 or 20/40 Snellen) either with or without a glare source present (e.g., Brightness Acuity Tester) or with significant cataract related visual symptoms in the opinion of the investigator;

4. Potential postoperative best-corrected distance visual acuity (BCDVA) of 0.66 decimal (6/9 or 20/30 Snellen) or better;

5. Drives a car at least 1-2 times per month;

6. Corneal astigmatism:

1. Normal corneal topography

2. Predicted postoperative residual refractive cylinder based on a toric IOL calculator, taking surgically induced astigmatism (SIA) into account and using the posterior corneal astigmatism (PCA) option, must be less than 1.00 D in both eyes.

7. Clear intraocular media other than cataract in each eye;

8. Availability, willingness, sufficient cognitive awareness to comply with examination procedures;

9. Signed informed consent and HIPAA authorization or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries;

10. Ability to understand, read, and write in French.

Exclusion Criteria

1. Requiring an intraocular lens power needed to achieve emmetropia (spherical equivalent ± 0.50 D) outside the available range of +18.0 D to +30.0 D for the Model C0002 IOL or +16.5 D to +27.5 D for the Model ZCB00 IOL;

2. Pupil abnormalities (non-reactive, fixed pupils, or abnormally-shaped pupils);

3. Irregular corneal astigmatism;

4. Recent ocular trauma or ocular surgery that is not resolved/stable or may affect visual outcomes or increase risk to the subject;

5. Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery;

6. Subjects who may be expected to require retinal laser treatment during the study;

7. Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level of worse than 0.66 decimal (6/9 or 20/30 Snellen) during the study;

8. Inability to achieve keratometric corneal stability preoperatively as a result of recent contact lens usage;

9. Subjects with diagnosed degenerative visual disorders (e.g., retinal disorders such as macular degeneration) that are predicted to cause visual acuity losses to a level worse than 0.66 decimal (6/9 or 20/30 Snellen) during the study;

10. Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects;

11. Use of systemic or ocular medications that may affect vision;

12. Prior, current, or anticipated use during the course of the study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcomes or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery);

13. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.);

14. Poorly-controlled diabetes;

15. Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcomes of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.); NOTE: Controlled ocular hypertension without glaucomatous changes (optic nerve cupping and visual field loss) is acceptable.

16. Neurological or neurodegenerative disorders that affect locomotion and cognitive function (e.g., Muscular disorders, Parkinson's disease, Alzheimer's disease etc.);

17. Use of mobility aids, any injury or condition that may affect walking;

18. Subject has condition(s) associated with the fluctuation of hormones that could lead to refractive changes;

19. Concurrent participation in any other clinical trial or participation within 30 days prior to the preoperative visit.

• Minimum Eligible Age: 60 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Johnson & Johnson Surgical Vision, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Johnson & Johnson Surgical Vision, Inc. Clinical Trial

Role: STUDY_DIRECTOR

Johnson & Johnson Surgical Vision, Inc.

Locations

Centre Hospitalier National d'Ophtalmologie

Paris, Île-de-France Region, France

Rothschild Foundation Hospital

Paris, Île-de-France Region, France

Countries

France

Other Identifiers

PCOL106APV2

Identifier Type: -

Identifier Source: org_study_id